KRYS
KRYS
NASDAQ · Biotechnology

Krystal Biotech Inc

$300.88
+0.63 (+0.21%)
As of Nov 7, 1:20 AM ET ·
Financial Highlights (FY 2026)
Revenue
386.65M
Net Income
203.53M
Gross Margin
94.1%
Profit Margin
52.6%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 94.1% 49.6% 49.6% 49.6%
Operating Margin 41.4% 16.7% 15.8% 19.1%
Profit Margin 52.6% 12.4% 11.5% 12.6%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 386.65M 971.92M 894.90M 986.11M
Gross Profit 363.76M 481.90M 443.71M 488.93M
Operating Income 160.27M 162.40M 141.12M 188.02M
Net Income 203.53M 120.52M 102.54M 123.97M
Gross Margin 94.1% 49.6% 49.6% 49.6%
Operating Margin 41.4% 16.7% 15.8% 19.1%
Profit Margin 52.6% 12.4% 11.5% 12.6%
Rev Growth — +7.7% -5.6% +0.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 2.99B 2.71B 2.84B
Total Equity — 5.06B 4.99B 5.78B
D/E Ratio — 0.59 0.54 0.49
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 165.96M 242.82M 232.68M 229.91M
Free Cash Flow — 82.52M 69.44M 100.58M